EGFR and breast carcinoma: Although preclinical cell culture and xenograft studies suggest that EGFR targeted therapies hold promise for certain subtypes of breast cancer, clinical trials to date have shown responses in less than 10% of patients (Konecny et al, 2003; Arteaga and Truica, 2004; Kaklamani and O'Regan, 2004).